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Background: Managing multiple sclerosis (MS) treatment presents challenges for both patients 
and health care professionals. Effective communication between patients with MS and their 
neurologist is important for improving clinical outcomes and quality of life.
Methods: A closed-ended online market research survey was used to assess the current state 
of MS care from the perspective of both patients with MS ($18 years of age) and neurologists 
who treat MS from Europe and the US and to gain insight into perceptions of treatment expec-
tations/goals, treatment decisions, treatment challenges, communication, and satisfaction with 
care, based on current clinical practice.
Results: A total of 900 neurologists and 982 patients completed the survey, of whom 46% self-
identified as having remitting-relapsing MS, 29% secondary progressive MS, and 11% primary 
progressive MS. Overall, patients felt satisfied with their disease-modifying therapy (DMT); 
satisfaction related to comfort in speaking with their neurologist and participation in their DMT 
decision-making process. Patients who self-identified as having relapsing-remitting MS were 
more likely to be very satisfied with their treatment. Top challenges identified by patients in 
managing their DMT were cost, side effects/tolerability of treatment, and uncertainty if treat-
ment was working. Half of the patients reported skipping doses, but only 68% told their health 
care provider that they did so.
Conclusion: Several important differences in perception were identified between patients 
and neurologists concerning treatment selection, satisfaction, expectations, goals, and comfort 
discussing symptoms, as well as treatment challenges and skipped doses. The study results 
emphasize that patient/neurologist communication and patient input into the treatment decision-
making process likely influence patient satisfaction with treatment.
Keywords: health care provider survey, multiple sclerosis, patient-health care provider relation-
ship, patient survey, treatment expectations, treatment satisfaction
Introduction
Multiple sclerosis (MS) is usually diagnosed in the third and fourth decades of life and 
can lead to fixed and/or progressive neurological impairment with a significant impact 
on activity.1,2 The last two decades have seen the advent of both disease-modifying 
therapies (DMTs) and new symptomatic therapies, adding to the complexity of the 
decision-making process of DMT selection and MS symptom management.3,4 More 
emphasis is being placed on patient-reported outcomes to help measure clinical 
outcomes, capture the full impact of the disease, and to determine health care provider 
(HCP) reimbursement.5,6 Thus, effective communication between patients and their 
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HCPs becomes even more important for understanding 
the full impact of the disease to achieve optimal clinical 
outcomes.
Shared treatment decision making is promoted as 
representing good practice, and likely encourages treatment 
adherence and improves patient satisfaction. To be active 
participants in the DMT decision-making process, patients 
need to have adequate understanding of both their disease and 
the benefits/risks of treatments.7–9 Patients with MS who are 
well informed about their disease have significantly higher 
medication adherence than those who are not.10 The key ele-
ment to maintaining treatment adherence in patients with MS 
is an open and honest relationship between the patient and 
HCP.11 Determining perceived differences in communication 
effectiveness between patients and their neurologists is essen-
tial for improving clinical outcomes and quality of life.12,13
The aim of this study was to assess the current state of 
MS care from the perspective of both patients with MS and 
neurologists treating patients with MS, and to gain insight 
into perceptions of treatment expectations/goals, treatment 
decisions, treatment challenges, communication, and satis-
faction with care, based on current clinical practice.
Methods
survey design
Closed-ended questions for an online survey were developed 
to assess patient and neurologist attitudes, perceptions, and 
knowledge related to different aspects of MS, including the 
impact of disease on patients’ lives, patient and HCP rela-
tionships, availability and usefulness of MS informational 
resources, and the expectations for satisfaction and also 
challenges encountered with a chosen DMT for MS. The 
survey was designed from a market research perspective for 
hypothesis-generating purposes. Questions were developed by 
the State of MS Consortium, comprising representatives from 
Biogen, GCI Health, and a steering committee (authors of this 
manuscript) of international MS experts and patient advocacy 
representatives, in collaboration with Harris Poll. Parallel 
questions for patients and neurologists were designed to allow 
comparisons. The survey responses were single or multiple 
response, numeric text, or rated on a 4- to 5-point Likert scale 
(eg, “very important”, “important”, “somewhat important”, or 
“not at all important”; “strongly agree”, “somewhat agree”, 
“somewhat disagree”, or “strongly disagree”, respectively). 
As the nature of this online survey was blinded and non-
interventional, formal review and approval by the ethics review 
committee of the Hospital Vall d’Hebron was not required for 
this study. The study was carried out in accordance with the 
principles outlined in the Declaration of Helsinki.
selection and recruitment
Neurologists and patients from Italy, Germany, Spain, the 
UK, and the US were surveyed between March 18 and 
April 25, 2014.
Patients
Recruitment targets were set at 100–500 patients per country 
and recruitment continued until targets were met. Patients 
($18 years of age) who participated in the research were 
recruited from survey panels provided by Harris Poll and vet-
ted partners. Those invited to participate from the panels had 
previously agreed to participate in survey research, completed 
a double opt-in process, and identified themselves as having 
MS. Participating panel members were originally recruited 
into the survey panels using multiple methods (eg, directly, via 
banner ads, through other research). For this study, panelists 
were invited to participate in the research via email invitations. 
As access to the study was closed in each country once the 
recruitment target was met, determining the responder rate 
was not possible. A total of 2,023 panelists began the survey, 
with the 982 who completed it forming the analyzed cohort. 
Of those 1,047 invited panelists who started the survey but did 
not complete it, only 78 were determined to have met the age 
and diagnosis qualification criteria. The survey closed once the 
recruitment targets were met, so the responder rate could not be 
determined. Completion of the online survey questions deemed 
the qualify patients consented to participate in this study.
neurologists
For neurologists treating patients with MS, recruitment targets 
were set at 150–200 neurologists per country and recruitment 
continued until the targets were met. US neurologists were 
randomly selected from the database of the American Medi-
cal Association master file. Those selected received a postal 
mail letter inviting them to participate in the research and were 
provided a link and password to the online survey. European 
neurologists were originally recruited to survey panels in a man-
ner similar to patients from survey panels provided by Harris 
Poll and vetted partners and invited to participate in this survey 
via email. Neurologists had to have seen $1 patient with MS, on 
average, each year in their practice to be included in the survey. 
A total of 1,124 participants began the survey, with 900 who 
completed it forming the analyzed cohort. Of those 224 invited 
participants who started the survey but did not complete it, 80 
were determined to have met the inclusion criteria. The survey 
closed once the recruitment targets were met, so the responder 
rate could not be determined. Completion of the online survey 
questions deemed the qualify neurologists consented to partici-
pate in this study.
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For both neurologists and patients, specific subcategory 
quotas (eg, MS type, years in practice) within each country 
and audience were not predefined; thus, baseline demograph-
ics may have varied by country.
statistical analysis
In the US, patient results were weighted for sex, age, region, 
race/ethnicity, education, and income to align with the US MS 
patient population based on predetermined targets. The targets 
were based on a demographic profile derived from the polling 
company. Neurologist results were weighted for sex, region, 
and years in practice. US neurologist results were weighted to 
be representative of the American Medical Association neurolo-
gist population. No other countries were weighted individually 
because information on the population profiles was not avail-
able. Additional weights were applied to the total data to give 
each country equal representation in the overall results.
Descriptive statistics are reported for the total patient/
neurologist samples. Given the aim of the project was to 
identify themes that might justify further study, no correction 
was made for multiple comparisons. Statistically significant 
differences across the subgroups of interest for patients or 
neurologists were determined by an independent sample t-test 
of column proportions and means at the 95% confidence level. 
No statistical testing was performed across audiences because 
the question phrasing differed between patients and neurolo-
gists. The dataset results were reviewed and any trends and 
patterns for themes of interest have been presented.
Results
Demographics
Nine hundred neurologists (Table S1) and 982 patients 
(Table 1) completed the survey.
Patients
Patients surveyed most commonly identified themselves 
as having relapsing-remitting MS (RRMS; 46%), followed 
by secondary progressive MS (SPMS; 29%) and primary 
progressive MS (11%).
Baseline characteristics differed by country. More 
participating patients in the US self-identified as having 
RRMS than other countries, while more patients in Europe 
self-identified as having any form of progressive disease 
compared with the US (Table 1). Patients from the US and 
UK were older, on average, than patients from Germany, 
Italy, and Spain and subsequently reported a longer average 
time since MS diagnosis (Table 1). Overall, 62% of patients 
had at some stage taken a DMT for MS (63% for RRMS, 
68% for SPMS, and 52% for all others, including primary 
progressive MS, progressive relapsing MS [PRMS], and 
other/those who were not sure).
relationship and communication with 
hcPs
The majority of patients somewhat/strongly agreed that 
their neurologists were honest in setting expectations for 
therapy success (85%), had a good understanding of all 
aspects of MS (84%), and had an open dialogue with them 
(82%). Although most patients (83%) reported that they were 
somewhat/very comfortable speaking with the neurologist 
or most frequently seen HCP about MS, nearly 1:5 patients 
reported being uncomfortable speaking about difficulty 
walking (19%), tremors (19%), and muscle spasms (18%; 
Table S2). Sensitive symptoms such as sexual difficul-
ties (54%), bladder/bowel problems (28%), mood swings 
(26%), difficulty swallowing (21%), and cognitive/memory 
issues/trouble concentrating (21%) emerged as the most 
Table 1 Patient demographics
Characteristics Germany Italy Spain UK US Total
Patients (n) 146 100 100 125 511 982
Type of Ms (self-reported), %
rrMs 43 40 42 41 66a–d 46
sPMs 26e 35e 42a,d,e 26e 18 29
PPMs 11 10 9 17e 8 11
PrMs 13b–e 5 4 6 4 6
Other/not sure 7 10 3 10 5 7
Mean (sD) age (years) 44 (10)c 42 (12) 40 (10) 49 (13)a–c 50 (13)a–c 45 (12)
Female, % 71c 59c 44 74b,c 69c 63
Mean (median) time since Ms diagnosis (years) 11.8 (10)b,c 8.6 (5) 6.9 (5) 12.3 (10)b,c 14.3 (12)a–c 10.8 (8)
Participation in clinical trial for Ms, %
Yes, currently participating 9d 13d,e 10d,e 2 5 8
Yes, participated in the past but not currently 13 24a,e 28a,e 19e 10 19
no, i have never participated 78b,c 63 62 79b,c 85b,c 74
Notes: Weights were applied to the total data to give each country equal representation in the overall results. aSignificantly different than Germany. bSignificantly different 
than italy. cSignificantly different than Spain. dSignificantly different than the UK. eSignificantly different than the US.
Abbreviations: Ms, multiple sclerosis; PPMs, primary progressive multiple sclerosis; PrMs, progressive relapsing multiple sclerosis; rrMs, relapsing-remitting multiple 
sclerosis; sD, standard deviation; sPMs, secondary progressive multiple sclerosis.
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uncomfortable for patients to discuss. Only 2%–3% of 
neurologists identified symptoms such as difficulty in walk-
ing, tremors, and spasms as uncomfortable topics for their 
patients; however, they may have overestimated patients’ 
discomfort talking about those same sensitive symptoms, 
including sexual difficulties (87%), bladder/bowel problems 
(54%), mood swings (37%), and cognitive/memory issues/
trouble concentrating (37%; Table S2).
Communication appeared to be important in treatment 
satisfaction, as those who were satisfied with their DMT were 
more likely than those who were less satisfied to say that they 
were very comfortable speaking to their neurologist (64% vs 
43%, respectively; P,0.05) and were more likely to say they 
had an open dialogue with their HCP in which they could 
ask any questions they wanted (92% vs 80%, respectively; 
P,0.05). The majority of patients somewhat/strongly agreed 
that their neurologist was accessible when needed (71%).
cognitive impairment
More neurologists (74%) than patients (44%) felt MS has 
had a negative impact on the patients’ ability to perform 
cognitive tasks (Figure S1). When asked about MS symptoms 
they had experienced, 39% of patients reported cognitive/
memory issues/trouble concentrating (Table S3). Thirty-
seven percent of neurologists perceived their patients were 
not comfortable discussing cognitive impairment, whereas 
only 21% of patients were not comfortable discussing the 
problem with their neurologist (Table S2). While nearly all 
neurologists (95%) felt maintaining cognitive function was 
a very important/important part of their patients’ treatment 
goal, only 41% of patients who were currently taking DMTs 
reported it as part of their treatment goal.
Treatment selection, satisfaction, and 
expectations
Thirty-seven percent of patients reported that their HCP was 
the sole/primary DMT decision maker (Figure 1A), despite 
71% of neurologists indicating that most patients with MS 
prefer that they, the neurologist, decide which treatment is 
appropriate for them. The level of patient participation in the 
treatment decision-making process remained constant across 
MS disease subtypes (Figure 1A). Patients in Spain (n=55) 
were the most likely (42%) to say their HCP was the sole 
decision maker compared with only 9% in the UK (n=47), 
10% in the US (n=353), 14% in Italy (n=63), and 15% in 
Germany (n=125; Figure S2). Country-level results with small 
base size should be interpreted as directional in nature. Patients 
who were satisfied with their DMT were more likely to say that 
their expectations were very closely met than those who were 
not satisfied (67% vs 44%, respectively; P,0.05). More than 
half of patients who were currently taking DMTs (58%) were 
very satisfied/satisfied and 42% were somewhat/not at all satis-
fied (Figure 1B), but this varied by country. US patients were 
the most likely to be satisfied with their MS medication(s) and 
patients in Italy less likely to be satisfied than patients in most 
other countries (Figure S3). Most patients (69%) were opti-
mistic about their future, and these patients were more likely 
to say they were very satisfied/satisfied with their current DMT 
(66%) than those who were not optimistic (37%). Patients who 
self-identified as having RRMS were more likely to be very 
satisfied with their current DMT than those who identified as 
having SPMS or other types of MS (31% vs 17% and 16%, 
respectively; P,0.05). Patients who were satisfied with their 
DMT were more likely than others to report having been an 
equal partner or primary/sole decision maker in choosing their 
DMT (69% vs 58%, respectively; P,0.05). Most neurologists 
(92%) agreed that MS patients who provided input when 
choosing a treatment plan tended to be more satisfied with 
their treatment experience than those who did not.
Only approximately half of patients (53%) said that 
their DMT met the expectations set forth before treatment 
closely/very closely. More than 1:5 patients either said no 
expectations were set (12%) or they could not recall if they 
were set (10%).
Treatment choice and goals
Both patients and neurologists included safety and side 
effects as top factors that are important when making deci-
sions about DMTs (Figure S4). Patients’ top treatment goals 
for their current DMT included reducing relapse frequency 
(61%), slowing disability progression (60%), feeling bet-
ter (53%), and reducing relapse intensity (50%). Similarly, 
neurologists’ most important treatment goals for their patients’ 
current MS DMT were reducing relapse frequency (97% very 
important/important), slowing disability progression (97%), 
feeling better (92%), and reducing relapse intensity (93%).
Treatment challenges
Top challenges identified by patients in managing their DMT 
were cost, side effects/tolerability of treatment, and uncer-
tainty if treatment was working (Figure 2). Personal cost was 
identified as a challenge by more patients in the US than in 
Germany and the UK (36% vs 23% and 9%, respectively). 
Patients and neurologists were aligned in identifying top chal-
lenges, with the exception of cost, but differed in the frequency 
of their response (Figure 2). However, approximately half of 
neurologists also cited lack of acceptance of the disease, while 
only a few patients themselves reported this.
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skipped doses
Nearly half of patients (49%) reported never skipping doses 
of their DMT. Of the 51% of patients who reported skipping 
doses, only 68% told their HCP when they skipped a dose. 
The top reasons patients cited for skipping a DMT dose were 
forgot (43%), side effects (22%), and feeling better (15%; 
Table 2). However, neurologists believed that side effects 
(73%) were the main reason for skipping doses.
0\+&3ZDVWKHSULPDU\GHFLVLRQPDNHUZLWKVRPHLQSXWIURPPH
0\+&3ZDVWKHVROHGHFLVLRQPDNHU
,ZDVWKHSULPDU\GHFLVLRQPDNHUZLWKVRPHLQSXWIURPP\+&3
,ZDVWKHVROHGHFLVLRQPDNHU
0\+&3DQG,ZHUHHTXDOO\LQYROYHGLQWKHGHFLVLRQ

7RWDOQ 
5506Q 
6306Q 
2WKHUQ 
    $
2WKHUQ E
 
D
5506Q 

 D

6306Q 

D


6RPHZKDWVDWLVILHG 6DWLVILHG
1RWDWDOOVDWLVILHG 9HU\VDWLVILHG
6RPHZKDWVDWLVILHG
6DWLVILHG
1RWDWDOOVDWLVILHG
9HU\VDWLVILHG
7RWDO%
Figure 1 (A) Participation in DMT decision making and (B) satisfaction of patients with DMT.
Notes: (A) Qualified patients with MS who had taken prescription medications responded to the question, “How much input did you have in choosing your current/past 
disease-modifying medication(s), compared to your health care provider?” (B) n=463 patients with Ms who were currently taking prescription medication responded to the 
question, “Overall, how satisfied are you with your current disease-modifying multiple sclerosis medication(s)?” The other category includes PPMS, progressive relapsing 
multiple sclerosis, and other/not sure. aIndicates RRMS significantly different from SPMS and other, or SPMS and other significantly different from RRMS (P,0.05). bPlease 
note small base size; results should be interpreted as directional in nature. Total may exceed 100% due to rounding.
Abbreviations: DMT, disease-modifying therapy; hcP, health care provider; Ms, multiple sclerosis; PPMs, primary progressive multiple sclerosis; rrMs, relapsing-remitting 
multiple sclerosis; sPMs, secondary progressive multiple sclerosis.
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Discussion
This large global online survey evaluated MS patient and 
neurologist attitudes about treatment expectations and goals, 
treatment decisions, treatment challenges, communication, 
and satisfaction with care. Overall, patients and neurologists 
identified similar treatment goals and challenges. Patients 
who were satisfied with their current DMT were especially 
optimistic about the future. Patient input into their DMT 
decision-making process influences satisfaction, as does open 
communication, according to both patients and neurologists.
These results are consistent with another study that 
showed 79% of patients with MS preferred to take an 
active role in medical decision making.7 A shared medical 
decision-making process regarding DMT choice is important 
in MS because current therapies are disease modifying, not 
curative, and adherence is important to optimize clinical 
outcomes.14 Studies have suggested that shortcomings in 
communication and information provided by HCPs may 
affect the quality of care, which in turn may affect treatment 
adherence, clinical outcomes, and ultimately quality of life.2,15 
While high levels of satisfaction were noted in many aspects 
of MS management, important gaps were identified.
Key differences exist in the perceptions of patients and 
neurologists when discussing MS symptoms. Neurologists 
tend to overestimate their patients’ discomfort talking about 
difficult topics such as sexual difficulties, bladder/bowel 
problems, and cognitive impairment, but tend to underesti-
mate their discomfort discussing topics such as tremor and 
walking difficulty. These discrepancies could potentially 
lead to neurologists failing to identify and address modifiable 
symptoms. Cognition has been shown to be key in patients’ 
quality of life and therefore it is a very relevant symptom. 
Cognitive impairment was of lower importance to patients 
than relapses and disability progression in most responses. 
The low number of patients identifying cognition as a prob-
lem may be related, at least in part, to the lack of correlation 
between perceived and objective cognitive issues, a dispar-
ity which has been previously noted.16–19 However, because 
cognition was not assessed in this survey, we cannot rule 
out that a higher proportion of patients without cognitive 
problems completed the survey.
&RVWH[SHQVHSHUVRQDOO\DQGWRKHDOWKFDUHV\VWHP
6LGHHIIHFWVWROHUDELOLW\RIWUHDWPHQW
8QFHUWDLQW\LIWUHDWPHQWLVZRUNLQJ
0DQDJLQJVHULRXVULVNDVVRFLDWHGZLWKWUHDWPHQW
/DFNRIDFFHSWDQFHRIGLVHDVH
0RGHRIDGPLQLVWUDWLRQ
/DFNRIFOHDUH[SHFWDWLRQVDERXWKRZORQJ,WKH\ZLOOEHRQWKHUDS\














5HVSRQGHQWVVHOHFWLQJWKHRSWLRQ
3DWLHQWV 1HXURORJLVWV
Figure 2 Top challenges for managing disease-modifying therapies for Ms.
Notes: n=643 qualified patients with MS who had taken prescription medicines responded to the question, “What are the greatest challenges you face in managing your 
disease-modifying multiple sclerosis treatment?” n=900 neurologists responded to the question, “What do you feel are the greatest challenges your patients face in managing 
their disease-modifying multiple sclerosis treatment?” The 7 of 15 most frequently selected items by both patients and neurologists are shown. The percentage of respondents 
selecting each option is indicated as a data label for each bar.
Abbreviation: Ms, multiple sclerosis.
Table 2 reasons for skipping prescribed dose(s) of medication
Reason (%) Total
n=321
i simply forgot 43
i was experiencing side effects 22
i was feeling better 15
safety concerns 13
i did not think the treatment was working 12
Treatment did not make me feel better 11
i was no longer feeling better 10
i could no longer afford treatment 8
reasons that were beyond my control 11
Other 11
not sure/do not recall 8
Notes: All patients who had taken a disease-modifying therapy prescription medication 
and skipped doses answered the following question: “Which of the following, if any, 
are reasons why you skip doses of your disease-modifying medication? Please select 
all that apply.”
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
24
0.
22
5.
94
 o
n 
16
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2017:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
39
state of Ms survey
Clear communication between patients and HCPs is key 
for optimal MS care.12,13 For patients, understanding what 
treatment will, and perhaps more importantly, will not do is 
important. Nearly one-third of patients who skipped doses 
did not tell their HCP, reinforcing the fact that patient adher-
ence should be routinely evaluated. Forgetting was cited at 
a similar rate in the Global Adherence Project observational 
study (50%)20 as in this survey (43%). Neurologists felt the 
main reason for non-adherence was side effects, indicating 
they are not aligned with patients on the main reasons for 
non-adherence. Identified treatment challenges also may 
affect adherence. For neurologists to effectively address 
non-adherence, they must understand patients’ reasons for 
non-adherence, dose skipping patterns, and treatment chal-
lenges for individual patients.
limitations
The results of this study should be interpreted with cau-
tion, particularly concerning the representativeness of the 
unweighted populations (ie, European patients and neurolo-
gists). The European results are only representative of the 
patients and neurologists who completed the survey and 
cannot reliably be extrapolated to the entire MS population/
treating neurologists. Although the translations were verified 
by native speakers, the multinational and multilingual nature 
of the survey may influence the results. Given the survey 
recruitment design and selection, response biases are pos-
sible and should be considered when interpreting the results. 
Patient recruitment targets were set for the total population 
per country without subtargets based on MS disease type; 
therefore, disease subtypes were not actively balanced across 
countries. This lack of balancing may be the reason for the 
unexpectedly high number of patients who identified as 
having PRMS in Germany compared with other countries 
or it may be an inconsistency in translation of the definition 
of PRMS. Also, we do not know which, if any, participating 
patients came from the same practices as the neurologists due 
to the independent recruitment of patients and neurologists. 
Therefore, the analysis represents both different perceptions 
and potentially different disease courses, treatment experi-
ences, and patient–HCP interactions. Further, although 
the survey’s online approach allowed for a relatively large 
(900 neurologists and .900 patients) sample and an oppor-
tunity for respondents to answer sensitive questions honestly 
without introducing the bias of an interviewer, a bias asso-
ciated with respondent self-selection may exist. We do not 
have data on the percentage of patients and neurologists who 
completed the survey compared with those who received the 
survey. The survey also is limited in that cognition was not 
assessed so, potentially, only patients with less cognitive 
impairment completed the survey. Finally, the differences 
in the importance and role of treatment cost between coun-
tries should be interpreted with caution, because the cause 
of these differences is likely due to the different health care 
systems. Along with costs, different health care systems also 
can bias perceptions with regard to treatment satisfaction 
and value of care.21
Conclusion and recommendations
The results presented offer insight into differences between 
the perceptions of patients and neurologists and highlight 
differences in priorities for choosing a MS therapy. The study 
was aimed at identifying themes that might warrant further 
study with more robust methodology and was not in itself 
aiming to provide definitive statistics. Providing information 
that raises awareness of the importance of patient/neurologist 
collaboration and actions that can enhance these relationships 
should be considered. Therefore, a collaborative approach 
for setting appropriate treatment expectations and greater 
patient input in therapy choice is key for improving treatment 
satisfaction and adherence.
Based on these data, some action points were identified: 
1) for HCPs, develop effective tools to improve communica-
tion, improving recognition of patients’ priorities, including 
patient-related outcomes; 2) for patients, develop educational 
programming that aids in learning about the disease and 
how to more actively participate in all aspects of decision 
making, thus working to become better self-advocates; and 
3) opportunities for professional organizations (eg, European 
Academy of Neurology, American Academy of Neurology) 
and patient organizations (eg, European Multiple Sclerosis 
Platform) to work together to raise awareness of discrepan-
cies in perceptions that exist between patients and HCPs.
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Supplementary materials
Table S1 neurologist demographics
Characteristics Germany Italy Spain UK US Total
neurologists (n) 200 200 150 150 200 900
Years in practice, n (%)
#10 80 (40)b,e 57 (29) 50 (33)e 65 (43)b,e 45 (23) 302 (34)
11–20 78 (39)b 59 (30) 67 (45)b,e 61 (41)b 63 (32) 334 (37)
21–30 36 (18) 59 (30)a,c,d 26 (17) 16 (11) 49 (24)d 180 (20)
$31 6 (3) 25 (13)a,c,d 7 (5) 8 (5) 43 (22)a–d 85 (9)
Mean (sD) age (years) 47 (8)c,d 47 (10)c,d 44 (8) 42 (8) 51 (11)a–d 46 (10)
Female, n (%) 39 (20) 76 (38)a,e 52 (35)a 59 (39)a,e 53 (27) 283 (32)
Average number of patients with Ms seen in year 194e 174e 170e 235b,c,e 124 180
Notes: Percentages may not add to 100 due to rounding. Weights were applied to the total data to give each country equal representation in the overall results. aSignificantly 
different than germany. bSignificantly different than Italy. cSignificantly different than Spain. dSignificantly different than the UK. eSignificantly different than the US.
Abbreviations: Ms, multiple sclerosis; sD, standard deviation.
Table S2 symptoms patients are not comfortable discussing with neurologist
Symptoms (%) Total patients
(variable)
Total neurologists
n=900
Sexual difficulties 54 87
Bladder/bowel problems 28 54
Mood swings 26 37
Difficulty swallowing 21 4
cognitive/memory issues/trouble concentrating 21 37
Difficulty walking 19 3
Tremors 19 2
Muscle spasms 18 2
Pain 17 4
Vision problems 17 3
Fatigue 16 6
Dizziness/lightheadedness 16 2
speech problems 16 5
Difficulties with fine motor tasks 15 5
impaired balance/tendency to fall 15 4
Tingling/“pins and needles” sensations, itching 14 2
numbness/impaired sensation 13 2
impaired upper limb function 12 2
none n/A 8
Notes: Survey question: “Which of the following symptoms, if any, are you not comfortable talking about with your neurologist you see the most for your multiple sclerosis?/
Which of the following symptoms, if any, do you think your multiple sclerosis patients are not comfortable talking about with you? Please select all that apply.” each symptom 
is based on those who experienced symptom (and also saw a health care provider in the last year).
Abbreviation: n/A, not applicable.
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Figure S1 impact of multiple sclerosis on the following aspects of your life/your patients’ lives.
Notes: Survey question: “How much of an impact, if any, has having multiple sclerosis had on each of the following aspects of your life/your patients’ lives?” Base: qualified 
patients who said the attribute was applicable; qualified neurologists who said they had an opinion on the attribute.
Table S3 symptoms experienced
Symptoms (%) Have experienceda
n=982
Experience dailyb
(variable)
Fatigue 71 74
Tingling/“pins and needles” sensations, itching 59 54
Difficulty walking 58 69
numbness/impaired sensation 56 56
impaired balance/tendency to fall 56 57
Pain 50 59
Muscle spasms 46 51
Mood swings 45 46
Vision problems 41 44
impaired upper limb function 40 46
Bladder/bowel problems 40 70
Dizziness or lightheadedness 39 38
cognitive/memory issues/trouble concentrating 39 61
Difficulties with fine motor tasks 33 53
Sexual difficulties 32 43
Tremors 27 43
speech problems 20 43
Difficulty swallowing 18 46
Other 4 46
Notes: aBase: all qualified patients who had experienced an applicable MS symptom. Survey question: “Which of the following symptoms of multiple sclerosis, if any, have 
you experienced? Please select all that apply.” bBase: all qualified patients who had experienced an applicable MS symptom. Survey question: “Thinking of the symptoms you 
have experienced, which of the following, if any, do you experience on a daily basis? Please think only of the symptoms you experience when you are not having a relapse. 
Please select all those that apply.
Abbreviation: Ms, multiple sclerosis.
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Figure S2 Patient participation in DMT decision making.
Notes: n=643 qualified patients with MS who had taken prescription medications responded to the question, “How much input did you have in choosing your current/past 
disease-modifying medication(s), compared to your health care provider?” Percentages (number) are shown. caution: country-level results with small base size should be 
interpreted as directional in nature and, as such, frequencies are shown in additon to the percentages where applicable.
Abbreviations: DMT, disease-modifying therapy; hcP, health care provider; Ms, multiple sclerosis.
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Figure S3 Patients’ satisfaction with DMTs.
Notes: n=463 qualified patients with MS who were currently taking prescription medication responded to the question, “Overall, how satisfied are you with your current 
disease modifiying MS medication(s)?” Percentages (numbers) are shown. Caution: country-level results with small base size should be interpreted as directional in nature 
and, as such, frequencies are shown in additon to the percentages where applicable.
Abbreviations: DMT, disease-modifying therapy; Ms, multiple sclerosis.
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
24
0.
22
5.
94
 o
n 
16
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal that focuses on the growing importance of patient 
 preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and their 
role in  developing new therapeutic modalities and compounds to optimize 
clinical  outcomes for existing disease states are major areas of interest for 
the  journal. This journal has been accepted for indexing on PubMed Central. 
The  manuscript management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit http://www.
dovepress.com/testimonials.php to read real quotes from published authors.
Patient Preference and Adherence 2017:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
45
state of Ms survey




 
 


 

:KHWKHUWKHWUHDWPHQWZLOOUHGXFHWKHVHYHULW\RIUHODSVHV
:KHWKHUWKHWUHDWPHQWZLOOUHGXFHWKHQXPEHURIUHODSVHV
:KHWKHUWKHWUHDWPHQWZLOOVORZGLVDELOLW\SURJUHVVLRQ
:KDWWKDWORQJWHUPHIIHFWVRIWKHWUHDWPHQWDUH
+RZWKHWUHDWPHQWZLOOLPSDFWP\WKHLUGDLO\OLIH
:KHWKHUWKHWUHDWPHQWLVVDIH
:KDWWKHSRWHQWLDOVLGHHIIHFWVDUH
:KHWKHUWKHWUHDWPHQWZLOOSUHYHQWOHVLRQVWKDWDSSHDURQ05,V
5HVSRQGHQWVVHOHFWLQJWKHRSWLRQ



3DWLHQWV 1HXURORJLVWV
Figure S4 Top factors important for patients to know when making decisions about disease-modifying treatments for Ms according to neurologists and patients.
Notes: n=982 qualified patients with MS responded to the question, “Which of the following, if any, are most important for you to know when making decisions about 
disease-modifying treatments?” n=900 qualified neurologists responded to the question, “Which of the following, if any, are the most important for your MS patients to 
know when making decisions about their disease-modifying treatments?” The top 8 of 20 factors selected by patients are shown. The percentage of respondents selecting 
each option is indicated as a data label for each bar.
Abbreviations: Mri, magnetic resonance imaging; Ms, multiple sclerosis.
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